Biểu đồ giá cổ phiếu INBX
INBX Dự đoán giá cổ phiếu
Inhibrx Biosciences Inc
$95.31
0.17%
$0.17
Khi đóng cửa: Jun 25, 16:00:00 GMT-4
$95.31
0%
$0
Phiên sau giờ: Jun 25, 17:40:53 GMT-4
Quay lại
Inhibrx Biosciences Inc (INBX) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$95.14
Giá mở cửa
$95.57
Phạm vi ngày
$90.93 - $98.5
Phạm vi 52 tuần
$12.24 - $155.29
Khối lượng
279.1K
Khối lượng trung bình
337.2K
Tỷ suất cổ tức
--
EPS (TTM)
-6.24
Vốn hóa thị trường
$1.3B
INBX là gì?
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 109 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
